Recent Updates
Recently added Catalysts
EXOZ Positive Sentiment

eXoZymes Inc. Announces Closing of $6 Million Public Offering

Wednesday, June 17, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: eXoZymes Inc. has successfully closed a public offering of common stock and warrants, raising $6 million. The company focuses on AI-enhanced enzymes that convert feedstock into nutraceuticals and novel medicines. This funding is expected to support their innovative projects in the biopharma sector.
Price reaction · baseline $6.33 (2026-06-17 close) · hit after-hours · 2 other EXOZ headline(s) in the window, move may be shared
day 0 close
+23.7%
day 1 · peak
+29.2%
day 3
+12.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Successful closing of a public offering
  • Company is pioneering AI-enhanced enzymes
  • Potential for valuable nutraceuticals and medicines

Full Press Release Details

Los Angeles, CA -- June 17, 2026 -- eXoZymes Inc. (NASDAQ: EXOZ) (“eXoZymes” or “Company”), a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines, today announced the closing of its previously announced underwritten public offering of common stock and warrants.

Frequently Asked Questions

What was the amount raised in eXoZymes' public offering?

eXoZymes raised $6 million through its public offering.

What does eXoZymes focus on?

eXoZymes specializes in AI-enhanced enzymes for nutraceuticals and medicines.

When was the public offering announced?

The public offering was announced on June 17, 2026.

ShareAdd on Google
Tags: EXOZ Viatris Investor Conferences Healthcare eXoZymes public offering AI-enhanced enzymes nutraceuticals
Last updated: Jun 17, 2026

Biotech snapshot

Cash runway
$6M liquidity · $1M/mo burn
~10 mo
Medium dilution risk